Selective Immunosuppressants

DrugDrug NameDrug Indication
DB00075MuromonabFor treatment of organ transplant recipients, prevention of organ rejection
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00092AlefaceptAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
DB00095EfalizumabFor the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
DB00098Antithymocyte immunoglobulin (rabbit)For prevention of renal transplant rejection
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB01024Mycophenolic acidFor the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
DB01097LeflunomideFor the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
DB01257EculizumabEculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy[L6919,A2246], and neuromyelitis optica spectrum disorder (NMOSD).[L6916]
DB01281AbataceptFor the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB05676ApremilastApremilast is indicated for the treating of active psoriatic arthritis in adults, for the treating of active moderate to severe psoriatic arthritis in patients who are eligible for phototherapy and systemic treatment. In addition, apremilast is now indicated for the treatment of oral ulcers associated with Behcet's disease in adults.[L7501]
DB06662AbetimusInvestigated for use/treatment in kidney disease and systemic lupus erythematosus.
DB06681BelataceptFor prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
DB08868FingolimodFingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
DB08879BelimumabAdjunct treatment for auto-antibody-positive active systemic lupus erythematosus (SLE). The intravenous injectable form is the only FDA approved treatment for pediatric patients with SLE.
DB08880TeriflunomideUsed in the treatment of relapsing forms of multiple sclerosis (MS).
DB08895TofacitinibFor the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
DB09033VedolizumabVedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
DB09312Antilymphocyte immunoglobulin (horse)For prevention of renal transplant rejection and for the treatment of aplastic anemia.
DB12692GusperimusNot Available
DB13241BegelomabNot Available
DB00242CladribineFor the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
DB11817BaricitinibIndicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.
DB11988OcrelizumabIndicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis [FDA Label].
DB12612OzanimodNot Available
DB14724EmapalumabEmapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.[L4840] The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure.[A38676] This condition is usually developed and present the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen and a lower number of blood cells.[L4840]
DB14762RisankizumabThis drug is for the treatment of moderate-to-severe plaque psoriasis in adults who are eligible to receive systemic therapy or phototherapy based on their disease process.[FDA label]
DrugDrug NameTargetType
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00092AlefaceptT-cell surface antigen CD2target
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00092AlefaceptComplement C1r subcomponenttarget
DB00092AlefaceptComplement C1q subcomponent subunit Atarget
DB00092AlefaceptComplement C1q subcomponent subunit Btarget
DB00092AlefaceptComplement C1q subcomponent subunit Ctarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00092AlefaceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00877SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00877SirolimusCytochrome P450 3A4enzyme
DB00877SirolimusSerine/threonine-protein kinase mTORtarget
DB00877SirolimusFibroblast growth factor 2target
DB00877SirolimusCytochrome P450 3A5enzyme
DB00877SirolimusCytochrome P450 3A7enzyme
DB00877SirolimusMultidrug resistance protein 1transporter
DB00877SirolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusMultidrug and toxin extrusion protein 1transporter
DB01024Mycophenolic acidInosine-5'-monophosphate dehydrogenase 2target
DB01024Mycophenolic acidInosine-5'-monophosphate dehydrogenase 1target
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-1enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-9enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 2B7enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-7enzyme
DB01024Mycophenolic acidUDP-glucuronosyltransferase 1-6enzyme
DB01097LeflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB01097LeflunomideCytochrome P450 1A2enzyme
DB01097LeflunomideCytochrome P450 2C9enzyme
DB01097LeflunomideAryl hydrocarbon receptortarget
DB01097LeflunomideProtein-tyrosine kinase 2-betatarget
DB01097LeflunomideATP-binding cassette sub-family G member 2transporter
DB01257EculizumabComplement C5target
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB01590EverolimusSerine/threonine-protein kinase mTORtarget
DB01590EverolimusCytochrome P450 3A4enzyme
DB01590EverolimusSolute carrier organic anion transporter family member 1B1transporter
DB01590EverolimusSolute carrier organic anion transporter family member 1B3transporter
DB01590EverolimusSolute carrier organic anion transporter family member 1A2transporter
DB05676ApremilastPhosphodiesterase isozyme 4target
DB05676ApremilastCytochrome P450 3A4enzyme
DB05676ApremilastCytochrome P450 2A6enzyme
DB05676ApremilastCytochrome P450 1A2enzyme
DB06681BelataceptT-lymphocyte activation antigen CD86target
DB06681BelataceptT-lymphocyte activation antigen CD80target
DB08868FingolimodLeukotriene-B(4) omega-hydroxylase 1enzyme
DB08868FingolimodSphingosine 1-phosphate receptor 5target
DB08868FingolimodSphingosine kinase 1enzyme
DB08868FingolimodCytochrome P450 2E1enzyme
DB08868FingolimodCytochrome P450 4F12enzyme
DB08868FingolimodHistone deacetylase 1target
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08880TeriflunomideATP-binding cassette sub-family G member 2transporter
DB08880TeriflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB08880TeriflunomideCytochrome P450 2C8enzyme
DB08880TeriflunomideSolute carrier organic anion transporter family member 1B1transporter
DB08880TeriflunomideCytochrome P450 1A2enzyme
DB08895TofacitinibNon-receptor tyrosine-protein kinase TYK2target
DB08895TofacitinibCytochrome P450 3A4enzyme
DB08895TofacitinibCytochrome P450 2C19enzyme
DB08895TofacitinibTyrosine-protein kinase JAK2target
DB08895TofacitinibTyrosine-protein kinase JAK1target
DB08895TofacitinibTyrosine-protein kinase JAK3target
DB08895TofacitinibSerum albumincarrier
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB00242CladribinePurine nucleoside phosphorylasetarget
DB00242CladribineDNAtarget
DB00242CladribineDeoxycytidine kinaseenzyme
DB00242CladribineRibonucleoside-diphosphate reductase large subunittarget
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2target
DB00242CladribineRibonucleoside-diphosphate reductase subunit M2 Btarget
DB00242CladribineDNA polymerase alpha catalytic subunittarget
DB00242CladribineDNA polymerase epsilon catalytic subunit Atarget
DB00242CladribineDNA polymerase epsilon subunit 2target
DB00242CladribineDNA polymerase epsilon subunit 3target
DB00242CladribineDNA polymerase epsilon subunit 4target
DB00242CladribineATP-binding cassette sub-family G member 2transporter
DB00242CladribineSolute carrier family 28 member 3transporter
DB11817BaricitinibSolute carrier family 22 member 8transporter
DB11817BaricitinibATP-binding cassette sub-family G member 2transporter
DB11817BaricitinibMultidrug and toxin extrusion protein 2transporter
DB11817BaricitinibCytochrome P450 3A4enzyme
DB11817BaricitinibTyrosine-protein kinase JAK1target
DB11817BaricitinibTyrosine-protein kinase JAK2target
DB11817BaricitinibSolute carrier family 22 member 6transporter
DB11817BaricitinibSolute carrier family 22 member 2transporter
DB11817BaricitinibSolute carrier organic anion transporter family member 1B3transporter
DB11817BaricitinibProtein-tyrosine kinase 2-betatarget
DB11817BaricitinibTyrosine-protein kinase JAK3target
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB14724EmapalumabInterferon gammatarget
DB14762RisankizumabInterleukin-23target